The DOI matches its Crossref record; 135 of the 135 references it cites were found in a registry or an index.
Cytokine Alterations in Schizophrenia: An Updated Review
Open accessAbstract
Schizophrenia, a multisystem disorder with an unknown etiology, is associated with several immune dysfunctions, including abnormal levels of circulating cytokines. In this review, we investigated the changes of cytokines in schizophrenic patients, their connection with behavioral symptoms severity and their potential clinical implications. We also assessed the possible causative role of abnormal cytokine levels in schizophrenia pathogenesis. Based on meta-analyses, we categorized cytokines according to their changes in schizophrenic patients into four groups: (1) increased cytokines, including interleukin (IL)-6, tumor necrosis factor (TNF)-α, IL-1β, IL-12, and transforming growth factor (TGF)-β, (2) non-altered cytokines, including IL-2, IL-4, and IL-17, (3) increased or non-altered cytokines, including IL-8 and interferon (IFN)-γ, and (4) IL-10 with increased, decreased, and non-altered levels. Notably, alterations in cytokines may be variable in four different categories of SP, including first-episode and drug-naïve, first-episode and non-drug-naïve, stable chronic, and chronic in acute relapse. Furthermore, disease duration, symptoms severity, incidence of aggression, and cognitive abilities are correlated with levels of certain cytokines. Clinical implications of investigating the levels of cytokine in schizophrenic patients include early diagnosis, novel therapeutic targets development, patient stratification for choosing the best therapeutic protocol, and predicting the prognosis and treatment response. The levels of IL-6, IL-8, IFN-γ, IL-2 are related to the treatment response. The available evidence shows a potential causative role for cytokines in schizophrenia development. There is a substantial need for studies investigating the levels of cytokines before disease development and delineating the therapeutic implications of the disrupted cytokine levels in schizophrenia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Positive and Negative Syndrome Scale (PANSS) for schizophrenia.
Kay, S. R., Fiszbein, A., & Opler, L. A. (1987) · Schizophrenia Bulletin · doi:10.1093/schbul/13.2.261 · Cited by 21,378
Biological insights from 108 schizophrenia-associated genetic loci
Schizophrenia Working Group of the Psychiatric Genomics Consortium (2014) · Nature · doi:10.1038/nature13595 · Cited by 7,577
The environment and disease: association or causation?
Hill, A. B. (2015) · Journal of the Royal Society of Medicine · doi:10.1177/0141076814562718 · Cited by 7,285
The Environment and Disease: Association or Causation?
Hill, A. B. (1965) · Proceedings of the Royal Society of Medicine · doi:10.1177/003591576505800503 · Cited by 6,974
Clozapine for the Treatment-Resistant Schizophrenic: A Double-blind Comparison With Chlorpromazine
Kane, J. (1988) · Archives of General Psychiatry · doi:10.1001/archpsyc.1988.01800330013001 · Cited by 4,156
Randolph, C., Tierney, M. C., Mohr, E., & Chase, T. N. (1998) · Journal of Clinical and Experimental Neuropsychology · doi:10.1076/jcen.20.3.310.823 · Cited by 2,519
Remission in Schizophrenia: Proposed Criteria and Rationale for Consensus
Andreasen, N. C., Carpenter, W. T., Kane, J. M., Lasser, R. A., Marder, S. R., & Weinberger, D. R. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.3.441 · Cited by 2,343
Writing narrative literature reviews for peer-reviewed journals: secrets of the trade
Green, B. N., Johnson, C. D., & Adams, A. (2006) · Journal of Chiropractic Medicine · doi:10.1016/s0899-3467(07)60142-6 · Cited by 2,224 · cited 1×
“Therefore, all the limitations of narrative reviews may apply to this study (136).”
BackgroundThe clinical global impressions scale: applying a research tool in clinical practice.
Busner, J., & Targum, S. D. (2007) · PubMed · Cited by 2,185
A Systematic Review of the Prevalence of Schizophrenia
Saha, S., Chant, D., Welham, J., & McGrath, J. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020141 · Cited by 2,168
Dinarello, C. A. (2000) · Chest · doi:10.1378/chest.118.2.503 · Cited by 2,045
Meta-Analysis of Cytokine Alterations in Schizophrenia: Clinical Status and Antipsychotic Effects
Miller, B. J., Buckley, P., Seabolt, W., Mellor, A., & Kirkpatrick, B. (2011) · Biological Psychiatry · doi:10.1016/j.biopsych.2011.04.013 · Cited by 1,742
Goldsmith, D. R., Rapaport, M. H., & Miller, B. J. (2016) · Molecular Psychiatry · doi:10.1038/mp.2016.3 · Cited by 1,683
Common variants conferring risk of schizophrenia
†Genetic Risk and Outcome in Psychosis (GROUP), Stefansson, H., Ophoff, R. A., Steinberg, S., Andreassen, O. A., Cichon, S., Rujescu, D., Werge, T., Pietiläinen, O. P. H., Mors, O., et al. (2009) · Nature · doi:10.1038/nature08186 · Cited by 1,677 · cited 1×
“Based on genomewide association studies, schizophrenia is also associated with specific major histocompatibility complex (MHC) region genes (14).”
BackgroundRaison, C. L., Rutherford, R. E., Woolwine, B. J., Shuo, C., Schettler, P., Drake, D. F., Haroon, E., & Miller, A. H. (2013) · JAMA Psychiatry · doi:10.1001/2013.jamapsychiatry.4 · Cited by 1,617
Inflammatory cytokines in depression: neurobiological mechanisms and therapeutic implications
Felger, J. C., & Lotrich, F. E. (2013) · Neuroscience · doi:10.1016/j.neuroscience.2013.04.060 · Cited by 1,180
Kaplan and Sadock's Comprehensive Text Book of Psychiatry
Saldanha, D. (2005) · Medical Journal Armed Forces India · doi:10.1016/s0377-1237(05)80189-3 · Cited by 1,166
Inflammation and immunity in schizophrenia: implications for pathophysiology and treatment
Khandaker, G. M., Cousins, L., Deakin, J., Lennox, B. R., Yolken, R., & Jones, P. B. (2015) · The Lancet Psychiatry · doi:10.1016/s2215-0366(14)00122-9 · Cited by 926
Miller, A. H., Haroon, E., Raison, C. L., & Felger, J. C. (2013) · Depression and Anxiety · doi:10.1002/da.22084 · Cited by 892
Obesity, inflammation, and the gut microbiota
Cox, A. J., West, N. P., & Cripps, A. W. (2015) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(14)70134-2 · Cited by 869
Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review
Potvin, S., Stip, E., Sepehry, A. A., Gendron, A., Bah, R., & Kouassi, E. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.09.024 · Cited by 858
Khandaker, G. M., Pearson, R. M., Zammit, S., Lewis, G., & Jones, P. B. (2014) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2014.1332 · Cited by 846
Marsland, A. L., Walsh, C., Lockwood, K., & John-Henderson, N. A. (2017) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2017.01.011 · Cited by 691
Fedak, K. M., Bernal, A., Capshaw, Z. A., & Gross, S. (2015) · Emerging Themes in Epidemiology · doi:10.1186/s12982-015-0037-4 · Cited by 680
Inflammation in schizophrenia: pathogenetic aspects and therapeutic considerations.
Müller, N. (2018) · Schizophrenia Bulletin · doi:10.1093/schbul/sby024 · Cited by 648
Understanding the functions and relationships of the glymphatic system and meningeal lymphatics
Louveau, A., Plog, B. A., Antila, S., Alitalo, K., Nedergaard, M., & Kipnis, J. (2017) · Journal of Clinical Investigation · doi:10.1172/jci90603 · Cited by 640
Pedersen, C. B., Mors, O., Bertelsen, A., Waltoft, B. L., Agerbo, E., McGrath, J. J., Mortensen, P. B., & Eaton, W. W. (2014) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2014.16 · Cited by 619
An introduction to immunology and immunopathology
Warrington, R., Watson, W., Kim, H. L., & Antonetti, F. R. (2011) · Allergy, Asthma & Clinical Immunology · doi:10.1186/1710-1492-7-s1-s1 · Cited by 596
Moreno-Küstner, B., Martín, C., & Pastor, L. (2018) · PLOS ONE · doi:10.1371/journal.pone.0195687 · Cited by 562 · cited 5×
“Based on meta-analyses, we categorized cytokines according to their changes in schizophrenic patients into four groups: (1) increased cytokines, including interleukin (IL)-6, tumor necrosis factor (TNF)-a, IL-1b, IL-12, and transforming growth factor (TGF)-b, (2) nonaltered cytokines, including IL-2, IL-4, and IL-17,…”
BackgroundInfluentialCytokine function in medication-naive first episode psychosis: A systematic review and meta-analysis
Upthegrove, R., Manzanares-Teson, N., & Barnes, N. M. (2014) · Schizophrenia Research · doi:10.1016/j.schres.2014.03.005 · Cited by 501 · cited 5×
“Moreover, several studies (including meta-analyses) found a significant increase in the levels of soluble IL-2 receptor (sIL-2R), levels of which might affect the level of IL-2 by binding with it, in FEDN patients and chronic patients who were stable or were experiencing an acute relapse or were recovering from one (2…”
BackgroundMethodResultInfluentialThe role of inflammation in schizophrenia
Müller, N., Weidinger, E., Leitner, B., & Schwarz, M. J. (2015) · Frontiers in Neuroscience · doi:10.3389/fnins.2015.00372 · Cited by 465
Cytokines and brain excitability
Galic, M. A., Riazi, K., & Pittman, Q. J. (2012) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2011.12.002 · Cited by 446
Srikanthan, K., Feyh, A., Visweshwar, H., Shapiro, J. I., & Sodhi, K. (2016) · International Journal of Medical Sciences · doi:10.7150/ijms.13800 · Cited by 443
Shechter, R., London, A., & Schwartz, M. (2013) · Nature Reviews Immunology · doi:10.1038/nri3391 · Cited by 403
Efficacy of Anti-inflammatory Agents to Improve Symptoms in Patients With Schizophrenia: An Update
Sommer, I. E., van Westrhenen, R., Begemann, M. J. H., de Witte, L. D., Leucht, S., & Kahn, R. S. (2014) · Schizophrenia Bulletin · doi:10.1093/schbul/sbt139 · Cited by 342
Zhou, X., Fragala, M. S., McElhaney, J. E., & Kuchel, G. A. (2010) · Current Opinion in Clinical Nutrition and Metabolic Care · doi:10.1097/mco.0b013e32833cf3bc · Cited by 327
The inflammatory response system in treatment-resistant schizophrenia: increased serum interleukin-6
Lin, A., Kenis, G., Bignotti, S., Tura, G.-J.-B., De Jong, R., Bosmans, E., Pioli, R., Altamura, C., Scharpé, S., & Maes, M. (1998) · Schizophrenia Research · doi:10.1016/s0920-9964(98)00034-6 · Cited by 321
Current Topics in Behavioral Neurosciences
Bowden, C. L. (2011) · Current topics in behavioral neurosciences · Cited by 318
Inflammatory Biomarkers and Risk of Schizophrenia: A 2-Sample Mendelian Randomization Study
Hartwig, F. P., Borges, M. C., Horta, B. L., Bowden, J., & Davey Smith, G. (2017) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.3191 · Cited by 302
The glutamate hypothesis of schizophrenia: evidence from human brain tissue studies
Hu, W., MacDonald, M. L., Elswick, D. E., & Sweet, R. A. (2015) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12547 · Cited by 286
Cortisol and Inflammatory Biomarkers Predict Poor Treatment Response in First Episode Psychosis
Mondelli, V., Ciufolini, S., Belvederi Murri, M., Bonaccorso, S., Di Forti, M., Giordano, A., Marques, T. R., Zunszain, P. A., Morgan, C., Murray, R. M., et al. (2015) · Schizophrenia Bulletin · doi:10.1093/schbul/sbv028 · Cited by 286
Pillinger, T., D’Ambrosio, E., McCutcheon, R., & Howes, O. D. (2019) · Molecular Psychiatry · doi:10.1038/s41380-018-0058-9 · Cited by 230
Antipsychotics' effects on blood levels of cytokines in schizophrenia: A meta-analysis
Tourjman, V., Kouassi, É., Koué, M.-È., Rocchetti, M., Fortin-Fournier, S., Fusar-Poli, P., & Potvin, S. (2013) · Schizophrenia Research · doi:10.1016/j.schres.2013.10.011 · Cited by 224
Cytokines, Oxidative Stress and Cellular Markers of Inflammation in Schizophrenia
Upthegrove, R., & Khandaker, G. M. (2019) · Current Topics in Behavioral Neurosciences · doi:10.1007/7854_2018_88 · Cited by 221
Serum and gene expression profile of cytokines in first-episode psychosis
Di Nicola, M., Cattaneo, A., Hepgul, N., Di Forti, M., Aitchison, K. J., Janiri, L., Murray, R. M., Dazzan, P., Pariante, C. M., & Mondelli, V. (2013) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2012.06.010 · Cited by 217
Çakici, N., van Beveren, N. J. M., Judge-Hundal, G., Koola, M. M., & Sommer, I. E. C. (2019) · Psychological Medicine · doi:10.1017/s0033291719001995 · Cited by 213
Misiak, B., Stańczykiewicz, B., Kotowicz, K., Rybakowski, J. K., Samochowiec, J., & Frydecka, D. (2018) · Schizophrenia Research · doi:10.1016/j.schres.2017.04.015 · Cited by 199
Zhang, X. Y., Zhou, D. F., Zhang, P. Y., Wu, G. Y., Cao, L. Y., & Shen, Y. C. (2002) · Schizophrenia Research · doi:10.1016/s0920-9964(01)00296-1 · Cited by 198
de Witte, L., Tomasik, J., Schwarz, E., Guest, P. C., Rahmoune, H., Kahn, R. S., & Bahn, S. (2014) · Schizophrenia Research · doi:10.1016/j.schres.2014.02.005 · Cited by 188
The Interaction of Nuclear Factor-Kappa B and Cytokines Is Associated with Schizophrenia
Song, X.-Q., Lv, L.-X., Li, W.-Q., Hao, Y.-H., & Zhao, J.-P. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.10.018 · Cited by 187
Towards an Immunophenotype of Schizophrenia: Progress, Potential Mechanisms, and Future Directions
Miller, B. J., & Goldsmith, D. R. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2016.211 · Cited by 184
Zhang, X. Y., Zhou, D. F., Cao, L. Y., Zhang, P. Y., Wu, G. Y., & Shen, Y. C. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n0710 · Cited by 183
Profiling inflammatory signatures of schizophrenia: A cross-sectional and meta-analysis study
Frydecka, D., Krzystek-Korpacka, M., Lubeiro, A., Stramecki, F., Stańczykiewicz, B., Beszłej, J. A., Piotrowski, P., Kotowicz, K., Szewczuk-Bogusławska, M., Pawlak-Adamska, E., et al. (2018) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2018.05.002 · Cited by 178
Boerrigter, D., Weickert, T. W., Lenroot, R., O’Donnell, M., Galletly, C., Liu, D., Burgess, M., Cadiz, R., Jacomb, I., Catts, V. S., et al. (2017) · Journal of Neuroinflammation · doi:10.1186/s12974-017-0962-y · Cited by 171
Is there a role for immune-to-brain communication in schizophrenia?
Khandaker, G. M., & Dantzer, R. (2016) · Psychopharmacology · doi:10.1007/s00213-015-3975-1 · Cited by 170
Stojanovic, A., Martorell, L., Montalvo, I., Ortega, L., Monseny, R., Vilella, E., & Labad, J. (2014) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2013.12.005 · Cited by 170
Lesh, T. A., Careaga, M., Rose, D. R., McAllister, A. K., de Water, J. V., Carter, C. S., & Ashwood, P. (2018) · Journal of Neuroinflammation · doi:10.1186/s12974-018-1197-2 · Cited by 160
Hope, S., Melle, I. S., Aukrust, P., Steen, N. E., Birkenaes, A. B., Lorentzen, S., Agartz, I., Ueland, T., & Andreassen, O. A. (2009) · Bipolar Disorders · doi:10.1111/j.1399-5618.2009.00757.x · Cited by 157
Al-Hakeim, H. K., Al-Rammahi, D. A., & Al-Dujaili, A. H. (2015) · Journal of Affective Disorders · doi:10.1016/j.jad.2015.04.044 · Cited by 152
Borovčanin, M., Jovanović, I., Radosavljevic, G. D., Dejanovic, S. D., Banković, D., Arsenijević, N., & Lukić, M. L. (2012) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2012.08.016 · Cited by 151
A comprehensive macrophage-T-lymphocyte theory of schizophrenia
Smith, R. S. (1992) · Medical Hypotheses · doi:10.1016/0306-9877(92)90117-u · Cited by 150
Cytokines and the neurodevelopmental basis of mental illness
Ratnayake, U., Quinn, T., Walker, D. W., & Dickinson, H. (2013) · Frontiers in Neuroscience · doi:10.3389/fnins.2013.00180 · Cited by 144
Goldsmith, D. R., Haroon, E., Miller, A. H., Strauss, G. P., Buckley, P. F., & Miller, B. J. (2018) · Schizophrenia Research · doi:10.1016/j.schres.2018.02.048 · Cited by 141
Capuzzi, E., Bartoli, F., Crocamo, C., Clerici, M., & Carrà, G. (2017) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2017.03.003 · Cited by 139
Frydecka, D., Misiak, B., Pawlak, E., Karabon, L., Tomkiewicz, A., Sedlaczek, P., Kiejna, A., & Beszłej, J. A. (2014) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-014-0533-5 · Cited by 133
Hope, S., Ueland, T., Steen, N. E., Dieset, I., Lorentzen, S., Berg, A. O., Agartz, I., Aukrust, P., & Andreassen, O. A. (2013) · Schizophrenia Research · doi:10.1016/j.schres.2012.12.023 · Cited by 131
Metcalf, S. A., Jones, P. B., Nordström, T., Timonen, M., Mäki, P. H., Miettunen, J., Jääskeläinen, E., Järvelin, M., Štochl, J., Murray, G. K., et al. (2016) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2016.09.008 · Cited by 129
Cho, M., Lee, T. Y., Kwak, Y. B., Yoon, Y. B., Kim, M., & Kwon, J. S. (2019) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867419835028 · Cited by 129
Dysregulation of chemo-cytokine production in schizophrenic patients versus healthy controls
Reale, M., Patruno, A., Lutiis, M. A. D., Pesce, M., Felaco, M., Giannantonio, M. D., Nicola, M. D., & Grilli, A. (2011) · BMC Neuroscience · doi:10.1186/1471-2202-12-13 · Cited by 128
Activation of Th17 cells in drug naïve, first episode schizophrenia
Ding, M., Song, X., Zhao, J., Gao, J., Li, X., Ge, Y., Wang, X., Harrington, A., Fan, X., & Lv, L. (2014) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2014.01.001 · Cited by 127
Hope, S., Hoseth, E. Z., Dieset, I., Mørch, R. H., Aas, M., Aukrust, P., Djurovic, S., Melle, I. S., Ueland, T., Agartz, I., et al. (2015) · Schizophrenia Research · doi:10.1016/j.schres.2015.04.004 · Cited by 121
Khandaker, G. M., Zammit, S., Burgess, S., Lewis, G., & Jones, P. B. (2018) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2017.11.020 · Cited by 118 · cited 1×
“in 2018, finding a strong association between a genetic variant of IL-6 receptor relating to the levels of IL-6 and CRP and development of schizophrenia (119).”
BackgroundDimitrov, D. H., Lee, S., Yantis, J., Valdez, C., Paredes, R. M., Braida, N., Velligan, D. I., & Walss‐Bass, C. (2013) · Schizophrenia Research · doi:10.1016/j.schres.2013.10.019 · Cited by 116
Noto, C. D. S., Maes, M. H. J., Ota, V., Teixeira, A. L., Bressan, R. A., Gadelha, A., & Brietzke, E. M. (2015) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2015.1062552 · Cited by 116
Altamura, A. C., Buoli, M., & Pozzoli, S. M. (2013) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.12089 · Cited by 114
Noto, M. N., Maes, M. H. J., Nunes, S. O. V., Ota, V., Rossaneis, A. C., Verri, W. A., Jr., Cordeiro, Q., Belangero, S. I., Gadelha, A., Bressan, R. A., et al. (2018) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2018.12.008 · Cited by 112
Effects of Risperidone on Cytokine Profile in Drug-Naive First-Episode Psychosis
Noto, C. D. S., Ota, V., Gouvêa, E. S., Rizzo, L. B., Spíndola, L., Honda, P. H. S., Cordeiro, Q., Belangero, S. I., Bressan, R. A., Gadelha, A., et al. (2014) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyu042 · Cited by 109
Kinetics of Cytokine Levels during Antipsychotic Treatment in Schizophrenia: A Meta-Analysis
Roméo, B., Brunet-Lecomte, M., Martelli, C., & Benyamina, A. (2018) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyy062 · Cited by 106
Song, X., Fan, X., Li, X., Zhang, W., Gao, J., Zhao, J., Harrington, A., Ziedonis, D. M., & Lv, L. (2013) · Psychopharmacology · doi:10.1007/s00213-013-3382-4 · Cited by 95
Cytokine and growth factor profiling in patients with the metabolic syndrome
Mirhafez, S. R., Pasdar, A., Avan, A., Esmaily, H., Moezzi, A., Mohebati, M., Meshkat, Z., Mehrad‐Majd, H., Eslami, S., Rahimi, H. R., et al. (2015) · British Journal Of Nutrition · doi:10.1017/s0007114515001038 · Cited by 94
Dahan, S., Bragazzi, N. L., Yogev, A., Bar-Gad, M., Barak, V., Amital, H., & Amital, D. (2018) · Psychiatry Research · doi:10.1016/j.psychres.2018.07.041 · Cited by 90
Xiu, M. H., Yang, G. G., Tan, Y., Chen, D. C., Tan, S., Wang, Z. R., Yang, F. D., Okusaga, O. O., Soares, J. C., & Zhang, X. Y. (2014) · Schizophrenia Research · doi:10.1016/j.schres.2014.03.024 · Cited by 86
Li, H., Zhang, Q., Li, N., Wang, F., Xiang, H., Zhang, Z., Su, Y., Huang, Y., Zhang, S., Zhao, G., et al. (2016) · Psychiatry Research · doi:10.1016/j.psychres.2016.10.061 · Cited by 85
Borovčanin, M., Jovanović, I., Radosavljevic, G. D., Dejanovic, S. D., Stefanović, V., Arsenijević, N., & Lukić, M. L. (2013) · Schizophrenia Research · doi:10.1016/j.schres.2013.03.027 · Cited by 84
Monocytic, Th1 and Th2 Cytokine Alterations in the Pathophysiology of Schizophrenia
Na, K.-S., & Kim, Y. (2007) · Neuropsychobiology · doi:10.1159/000111535 · Cited by 83
Maxeiner, H., Schneider, E. M., Kurfiss, S.-T., Brettschneider, J., Tumani, H., & Bechter, K. (2014) · Cytokine · doi:10.1016/j.cyto.2014.05.008 · Cited by 79
Sobiś, J., Rykaczewska-Czerwińska, M., Świętochowska, E., & Gorczyca, P. W. (2014) · Pharmacological Reports · doi:10.1016/j.pharep.2014.09.007 · Cited by 74
Antipsychotic treatment may alter T-helper (TH) 2 arm cytokines
Pae, C., Yoon, C., Kim, T., Kim, J.-J., Park, S., Lee, C., Lee, S.-J., Lee, C., & Paik, I. (2005) · International Immunopharmacology · doi:10.1016/j.intimp.2005.10.004 · Cited by 73
Lv, M. H., Tan, Y., Yan, S. X., Tian, L., Chen, D. C., Tan, S., Wang, Z. R., Yang, F. D., Yoon, J. H., Zunta‐Soares, G. B., et al. (2014) · Psychopharmacology · doi:10.1007/s00213-014-3650-y · Cited by 70
Haring, L., Koido, K., Vasar, V., Leping, V., Zilmer, K., Zilmer, M., & Vasar, E. (2015) · Schizophrenia Research · doi:10.1016/j.schres.2015.08.027 · Cited by 66
Inflammatory, cardio-metabolic and diabetic profiling of chronic schizophrenia
Balõtšev, R., Koido, K., Vasar, V., Janno, S., Kriisa, K., Mahlapuu, R., Ljubajev, Ü., Parksepp, M., Veiksaar, P., Volke, V., et al. (2016) · European Psychiatry · doi:10.1016/j.eurpsy.2016.05.010 · Cited by 66
Effects of depression on the cytokine profile in drug naïve first-episode psychosis
Noto, C. D. S., Ota, V., Santoro, M. L., Ortiz, B. B., Rizzo, L. B., Higuchi, C. H., Cordeiro, Q., Belangero, S. I., Bressan, R. A., Gadelha, A., et al. (2015) · Schizophrenia Research · doi:10.1016/j.schres.2015.01.026 · Cited by 65
Asevedo, E. D. M., Rizzo, L. B., Gadelha, A., Mansur, R. B., Ota, V., Berberian, A. D. A., Scarpato, B. S., Teixeira, A. L., Bressan, R. A., & Brietzke, E. M. (2014) · Physiology & Behavior · doi:10.1016/j.physbeh.2014.02.032 · Cited by 63
Şimşek, Ş., Yıldırım, V., Çim, A., & Kaya, S. (2016) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2015.0220 · Cited by 62
Markers of inflammation in schizophrenia: association vs. causation
Manu, P., Correll, C. U., Wampers, M., Mitchell, A. J., Probst, M., Vancampfort, D., & De Hert, M. (2014) · World Psychiatry · doi:10.1002/wps.20117 · Cited by 59
Kubistova, A., Horáček, J., & Novák, T. (2012) · PubMed · Cited by 59
Al-Asmari, A., & Khan, M. W. (2013) · Human & Experimental Toxicology · doi:10.1177/0960327113493305 · Cited by 57
Crespo‐Facorro, B., Carrasco-Marín, E., Pérez‐Iglesias, R., Pelayo‐Terán, J. M., Fernández-Prieto, L., Leyva‐Cobián, F., & Vázquez‐Barquero, J. L. (2008) · Psychiatry Research · doi:10.1016/j.psychres.2006.08.005 · Cited by 56
Szymona, K., Zdzisińska, B., Karakuła‐Juchnowicz, H., Kocki, T., Kandefer‐Szerszeń, M., Flis, M., Rosa, W., & Urbańska, E. M. (2017) · Neurotoxicity Research · doi:10.1007/s12640-017-9714-0 · Cited by 56
Zhu, F., Zhang, L., Liu, F., Wu, R., Guo, W., Ou, J., Zhang, X., & Zhao, J. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00296 · Cited by 50
Borovčanin, M., Janicijevic, S. M., Jovanović, I., Gajović, N., Arsenijević, N., & Lukić, M. L. (2018) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2018.00271 · Cited by 48
Hong, W., Zhao, M., Li, H., Peng, F., Wang, F., Li, N., Xiang, H., Su, Y., Huang, Y., Zhang, S., et al. (2016) · Scientific Reports · doi:10.1038/srep27584 · Cited by 47
Inflammation in individuals with schizophrenia – Implications for neurocognition and daily function
Kogan, S., Ospina, L. H., & Kimhy, D. (2018) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2018.09.016 · Cited by 47
Does Systemic Inflammation Play a Role in Pediatric Psychosis?
Falcone, T., Carlton, E. F., Lee, C., Janigro, M., Fazio, V., Forcén, F. E., Franco, K. S. N., & Janigro, D. (2013) · Clinical Schizophrenia & Related Psychoses · doi:10.3371/csrp.faca.030813 · Cited by 46
Aggression as an independent entity even in psychosis- the role of inflammatory cytokines
Das, S. K., Deuri, S. K., Sarmah, A., Pathak, K., Baruah, A., Sengupta, S., Mehta, S., Avinash, P., Kalita, K. N., & Hazarika, J. (2016) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2016.01.012 · Cited by 45
Association of biomarkers and depressive symptoms in schizophrenia
Noto, C. D. S., Gadelha, A., Belangero, S. I., Smith, M. D. A. C., de Aguiar, B. W., Panizzutti, B., Mari, J. D. J., Gama, C. S., Bressan, R. A., & Brietzke, E. M. (2011) · Neuroscience Letters · doi:10.1016/j.neulet.2011.10.042 · Cited by 44
Increase systemic levels of IL-23 as a possible constitutive marker in schizophrenia
Borovčanin, M., Jovanović, I., Dejanovic, S. D., Radosavljevic, G. D., Arsenijević, N., & Lukić, M. L. (2015) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2015.03.003 · Cited by 44
Xiu, M. H., Tian, L., Chen, S., Tan, Y., Chen, D. C., Chen, J., Chen, N., Yang, F. D., Licinio, J., Kosten, T. R., et al. (2016) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2016.03.005 · Cited by 43
Aziz, N. (2015) · Forum on Immunopathological Diseases and Therapeutics · doi:10.1615/forumimmundisther.2015014162 · Cited by 42
Functional Implications of the IL-23/IL-17 Immune Axis in Schizophrenia
Debnath, M., & Berk, M. (2016) · Molecular Neurobiology · doi:10.1007/s12035-016-0309-1 · Cited by 40
Nasal and systemic inflammatory profile after short term smoking cessation
Rodrigues, F. M. M., Ramos, D., Xavier, R. F., Ito, J. T., de Souza, A. P., Fernandes, R. A., Cecchini, R., Rossi, R. C., Macchione, M., de Toledo, A. C., et al. (2014) · Respiratory Medicine · doi:10.1016/j.rmed.2014.04.020 · Cited by 39
Zhang, Q., Hong, W., Li, H., Peng, F., Wang, F., Li, N., Xiang, H., Zhang, Z., Su, Y., Huang, Y., et al. (2017) · International Journal of Psychophysiology · doi:10.1016/j.ijpsycho.2017.02.001 · Cited by 39
Dunjić-Kostić, B., Jašović‐Gašić, M., Ivković, M., Radonjić, N. V., Pantović-Stefanović, M., Damjanović, A., Poznanović, S. T., Jovanović, A., Nikolić, T., & Petronijević, N. (2013) · PubMed · Cited by 37
Interleukin-17 Alteration in First-Episode Psychosis: A Meta-Analysis
Fang, X., Zhang, Y., Fan, W., Tang, W., & Zhang, C. (2017) · Complex Psychiatry · doi:10.1159/000481661 · Cited by 37
Reduced serum TNF alpha level in chronic schizophrenia patients with or without tardive dyskinesia
Tian, L., Tan, Y., Chen, D., Lv, M., Tan, S., Soares, J. C., & Zhang, X. Y. (2014) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2014.06.012 · Cited by 35
Ajami, A., Abedian, F., Hosseini, S. H., Akbarian, E., Alizadeh‐Navaei, R., & Taghipour, M. (2014) · PubMed · doi:10.22034/iji.2014.16780 · Cited by 35
Neuroimmune Biomarkers in Mental Illness
Herron, J. W., Nerurkar, L., & Cavanagh, J. (2018) · Current topics in behavioral neurosciences · doi:10.1007/7854_2018_45 · Cited by 35
Quality of life is associated with chronic inflammation in schizophrenia: a cross-sectional study
Faugère, M., Micoulaud‐Franchi, J., Alessandrini, M., Richieri, R. M., Faget, C., Auquier, P., Lançon, C., & Boyer, L. (2015) · Scientific Reports · doi:10.1038/srep10793 · Cited by 34
Lin, Y., Peng, Y., He, S., Xu, J., Shi, Y., Su, Y., Zhu, C., Zhang, X., Zhou, R., & Cui, D. (2018) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2018.01.020 · Cited by 34
Kappelmann, N., Khandaker, G. M., Dal, H., Štochl, J., Kosidou, K., Jones, P. B., Dalman, C., & Karlsson, H. (2018) · Psychological Medicine · doi:10.1017/s0033291718000831 · Cited by 34
Increased Peripheral Interleukin 10 Relate to White Matter Integrity in Schizophrenia
Fu, G., Zhang, W., Dai, J., Liu, J., Li, F. Y., Wu, D., Xiao, Y., Shah, C., Sweeney, J. A., Wu, M. C., et al. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00052 · Cited by 34
Inflammation and Elevation of Interleukin-12p40 in Patients with Schizophrenia
Bedrossian, N., Haidar, M., Fares, J., Kobeissy, F. H., & Fares, Y. (2016) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2016.00016 · Cited by 33
Wei, L., Du, Y., Wu, W., Fu, X., & Xia, Q. (2017) · Journal of Affective Disorders · doi:10.1016/j.jad.2017.10.002 · Cited by 33
Turhan, L., Batmaz, S., Koçbıyık, S., & Soygur, A. H. (2016) · Nordic Journal of Psychiatry · doi:10.3109/08039488.2015.1122079 · Cited by 29
de Campos-Carli, S. M., de Miranda, A. S., Dias, I. C. S., Oliveira, A. D. S., Cruz, B. F., Vieira, É. L. M., Rocha, N. P., Barbosa, I. G., Salgado, J. V., & Teixeira, A. L. (2017) · Comprehensive Psychiatry · doi:10.1016/j.comppsych.2017.01.008 · Cited by 29
Cytokine profile in drug-naïve, first episode patients with psychosis
Petrikis, P., Voulgari, P. V., Tzallas, A. T., Archimandriti, D. T., Skapinakis, P., & Mavreas, V. G. (2015) · Journal of Psychosomatic Research · doi:10.1016/j.jpsychores.2015.06.011 · Cited by 28
Serum cytokine profile in schizophrenic patients
Eftekharian, M. M., Omrani, M. D., Arsang‐Jang, S., Taheri, M. N., & Ghafouri‐Fard, S. (2018) · Human Antibodies · doi:10.3233/hab-180344 · Cited by 21
Plasma levels of IL‐1Ra are associated with schizophrenia
Zhou, Y., Peng, W., Wang, J., Zhou, W., Zhou, Y., & Ying, B. (2018) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.12794 · Cited by 21
Nishimon, S., Ohnuma, T., Takebayashi, Y., Katsuta, N., Takeda, M., Nakamura, T., Sannohe, T., Higashiyama, R. I., Kimoto, A., Shibata, N., et al. (2017) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2017.03.006 · Cited by 17
Immunity and psychiatric disorders: variabilities of immunity biomarkers are they specific?
Dubois, T., Reynaert, C., Jacques, D., Lepièce, B., Patigny, P., & Zdanowicz, N. (2018) · PubMed · Cited by 17
Metabolic Side Effects in Patients Using Atypical Antipsychotic Medications During Hospitalization
Dıkeç, G., Arabacı, L. B., Uzunoğlu, G., & Mızrak, S. D. (2018) · Journal of Psychosocial Nursing and Mental Health Services · doi:10.3928/02793695-20180108-05 · Cited by 14
Pillinger, T., D’Ambrosio, E., McCutcheon, R. A., & Howes, O. D. (2018) · Molecular Psychiatry · doi:10.1038/s41380-018-0275-2 · Cited by 14
Petrikis, P., Voulgari, P. V., Tzallas, A. T., Boumba, V. A., Archimandriti, D. T., Zambetas, D., Papadopoulos, I. A., Tsoulos, I. G., Skapinakis, P., & Mavreas, V. G. (2017) · Psychiatry Research · doi:10.1016/j.psychres.2017.07.002 · Cited by 11
Chu, C., Li, D., Chu, C., Wu, C., & Lu, T. (2018) · Psychiatry Investigation · doi:10.30773/pi.2017.11.10 · Cited by 11
Lee, H.-Y., & Kim, Y. (2010) · Acta Neuropsychiatrica · doi:10.1111/j.1601-5215.2009.00435.x · Cited by 6
Cited by
Association of Psychiatric Disorders With Mortality Among Patients With COVID-19
Nemani, K., Li, C., Olfson, M., Blessing, E. M., Razavian, N., Chen, J., Petkova, E., & Goff, D. C. (2021) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2020.4442 · Cited by 375
Role of IL-6 in the regulation of neuronal development, survival and function
Kummer, K. K., Zeidler, M., Kalpachidou, T., & Kress, M. (2021) · Cytokine · doi:10.1016/j.cyto.2021.155582 · Cited by 278
Abnormal synaptic pruning during adolescence underlying the development of psychotic disorders
Germann, M., Brederoo, S. G., & Sommer, I. E. C. (2021) · Current Opinion in Psychiatry · doi:10.1097/yco.0000000000000696 · Cited by 102
The Role of Cytokines in the Pathogenesis of Schizophrenia
Dawidowski, B., Górniak, A., Podwalski, P., Lebiecka, Z., Misiak, B., & Samochowiec, J. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10173849 · Cited by 102
Morris, G., Puri, B. K., Bortolasci, C. C., Carvalho, A., Berk, M., Walder, K., Moreira, E. G., & Maes, M. (2021) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2021.02.037 · Cited by 84
Metadata
- Authors
- Momtazmanesh, S., Zare-Shahabadi, A., & Rezaei, N.
- Venue
- Frontiers in Psychiatry
- Publisher
- Frontiers Media SA
- Published
- 2019-12-06
- Volume
- 10
- Pages
- 892-892
- ISSN
- 1664-0640 (ISSN-L)
- OpenAlex
- W2994279493
- Cited by
- 276
- References
- 135
- FWCI
- 7.66
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.